SYIN

Synbio International Inc. Expands its Board of Directors and Strengthens its Clinical Leadership with the Appointment of Dr. Nick Vatakis

Oct 22, 2025

Dr. Vatakis, appointed as Medical Director, brings decades of clinical trial leadership, advancing Synbio’s credibility and the integrity of its upcoming feasibility trial New York City, October 22, 2025 - PRISM MediaWire (Press Release Service - Press Release Distribution) - Synbio International Inc. (OTC: SYIN) (“Synbio” or the “Company”) is proud to announce the appointment of Dr. Nick Vatakis, MD as Medical Director. This appointment represents a major milestone in Synbio’s commitment to...

Synbio International Inc. Strengthens Strategic Alliance with FacialDx Inc. through Share Purchase and Warrant Agreements

Oct 8, 2025

The Share Purchase Agreement (SPA) secures an equity stake in FacialDx and secures ownership in its intellectual property by way of the shareholding. The SPA also enables Synbio to convert future clinical trial expenditures into additional equity in FacialDx at today’s valuation, unlocking substantial upside potential as FaciaDx also scales commercially. A Joint Trial Committee will be established to oversee the design, conduct, and reporting of all clinical studies, maximizing the likelihood...

NEWSROOM

Synbio International Inc. Expands its Board of Directors and Strengthens its Clinical Leadership with the Appointment of Dr. Nick Vatakis

Synbio International Inc. Strengthens Strategic Alliance with FacialDx Inc. through Share Purchase and Warrant Agreements

Contact Us